On 10 March 2026, The Pharma Letter reported that Roche subsidiary, Genentech, had begun legal proceedings before the Moscow Arbitration Court alleging patent infringement by Biocad’s biosimilar to Perjeta® (pertuzumab), Pertuvia™. Pertuvia™ was approved for sale in Russia in May 2025.
This Russian action comes shortly after Genentech commenced ITC proceedings in the US against Biocon’s pertuzumab biosimilar BMAB 1500 in February this year.
Roche and Genentech recently settled parallel BPCIA (US) proceedings against Shanghai Henlius and Organon relating to their pertuzumab biosimilar, Poherdy®. Poherdy® was approved by the FDA in November 2025 and received a positive CHMP opinion in early 2026.
Court action by Roche against Zydus regarding its pertuzumab biosimilar, Sigrima®, have been running since the approval of that product in India in 2024.
This multiplicity of pertuzumab-related legal actions reflects Roche’s concern, expressed in mid-2025, that biosimilar competition to Perjeta® would occur sooner than previously expected.
Other pertuzumab biosimilars been approved in Russia for R-Pharm and in India for Intas and Enzene. Further biosimilars are under development by Sandoz and EirGenix and through an Indo-Brazilian partnership.